TAT-BASED VACCINE COMPOSITIONS AND METHODS OF MAKING AND USING SAME
A Tat-based vaccine composition comprising at least one antigen coupled to at least one immunostimulatory lentivirus trans-activator of transcription (Tat) molecule wherein the antigen is a cancer antigen an infectious disease antigen or a fragment thereof and methods to treat disease by administering the Tat-based vaccine composition. An additional Tat-based vaccine composition comprising immunostimulatory lentivirus Tat is provided.
1 . A Tat-based vaccine composition comprising at least one antigen coupled to at least one immunostimulatory lentivirus trans-activator of transcription (Tat) molecule.
2 . The Tat-based vaccine composition of claim 1 wherein said antigen comprises a full length protein or a fragment thereof.
3 . The Tat-based vaccine composition of claim 1 wherein said antigen is a cancer antigen or an infectious disease antigen.
4 . The Tat-based vaccine composition of claim 3 wherein said cancer antigen is an antigen associated with cell growth.
5 . The Tat-based vaccine composition of claim 3 wherein said cancer antigen is human papilloma virus E7.
6 . The Tat-based vaccine composition of claim 1 wherein said immunostimulatory lentivirus Tat is oxidized human immunodeficiency virus-1 (HIV-1) Tat.
7 . The Tat-based vaccine composition of claim 1 wherein said immunostimulatory lentivirus Tat is the HIV-1 Tat wherein the amino acid proline at positions 6, 10 and 14 of SEQ ID NO. 1 is replaced with the amino acid glycine.
8 . The Tat-based vaccine composition of claim 1 wherein said immunostimulatory lentivirus Tat comprises the amino acid sequence of SEQ ID NO. 11.
9 . The Tat-based vaccine composition of claim 1 wherein said immunostimulatory lentivirus Tat and said antigen are linked through genetic engineering of their DNA to provide a recombinant protein.
10 . A method for treating disease comprising administering at least one Tat-based vaccine composition to a patient in need thereof.
11 . The method for treating disease according to claim 10 wherein said administering at least one Tat-based vaccine composition to a patient in need thereof further comprises administering said at least one Tat-based vaccine composition for the treatment of cancer.
12 . The method for treating disease according to claim 10 wherein said administering at least one Tat-based vaccine composition to a patient in need thereof further comprises administering said at least one Tat-based vaccine composition for the treatment of infectious disease.
13 . A Tat-based vaccine composition comprising immunostimulatory lentivirus Tat.
14 . The Tat-based vaccine composition of claim 13 further comprising at least one antigen wherein said antigen is a full length protein or a fragment thereof.
15 . The Tat-based vaccine composition of claim 13 wherein said immunostimulatory lentivirus Tat is oxidized HIV-1 Tat.
16 . The Tat-based vaccine composition of claim 13 wherein said immunostimulatory lentivirus Tat is HIV-1 Tat wherein the amino acid proline at positions 6, 10 and 14 of SEQ ID NO. 1 is replaced with the amino acid glycine.
17 . The Tat-based vaccine composition of claim 13 wherein said immunostimulatory lentivirus Tat comprises the amino acid sequence of SEQ ID NO. 11.